instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the dosage of drug 'MYCOPHENOLATE MOFETIL'? | Unmasking viral sequences by metagenomic next-generation sequencing in adult human blood samples during steroid-refractory/dependent graft-versus-host disease.
Viral infections are common complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Allo-HSCT recipients with steroid-refractory... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33487167 | 18,939,834 | 2021-01-24 |
What was the dosage of drug 'TACROLIMUS'? | Unmasking viral sequences by metagenomic next-generation sequencing in adult human blood samples during steroid-refractory/dependent graft-versus-host disease.
Viral infections are common complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Allo-HSCT recipients with steroid-refractory... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33487167 | 18,939,834 | 2021-01-24 |
What was the outcome of reaction 'Systemic mycosis'? | Unmasking viral sequences by metagenomic next-generation sequencing in adult human blood samples during steroid-refractory/dependent graft-versus-host disease.
Viral infections are common complications following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Allo-HSCT recipients with steroid-refractory... | Fatal | ReactionOutcome | CC BY | 33487167 | 18,939,834 | 2021-01-24 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cytomegalovirus viraemia'. | From TTP to Glomerulonephritis: A Lifetime of Lupus.
We report the case of a 56-year-old male patient, who over two decades, sequentially presented with a combination of clinical manifestations. These included thrombotic thrombocytopenic purpura (TTP), right leg deep vein thrombosis (DVT), and eventually constitutional... | ENOXAPARIN, HYDROXYCHLOROQUINE, MYCOPHENOLATE MOFETIL, PREDNISONE, RAMIPRIL | DrugsGivenReaction | CC BY | 33488735 | 20,220,475 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pseudomonas infection'. | From TTP to Glomerulonephritis: A Lifetime of Lupus.
We report the case of a 56-year-old male patient, who over two decades, sequentially presented with a combination of clinical manifestations. These included thrombotic thrombocytopenic purpura (TTP), right leg deep vein thrombosis (DVT), and eventually constitutional... | ENOXAPARIN, HYDROXYCHLOROQUINE, MYCOPHENOLATE MOFETIL, PREDNISONE, RAMIPRIL | DrugsGivenReaction | CC BY | 33488735 | 20,220,475 | 2021 |
What was the outcome of reaction 'Cytomegalovirus viraemia'? | From TTP to Glomerulonephritis: A Lifetime of Lupus.
We report the case of a 56-year-old male patient, who over two decades, sequentially presented with a combination of clinical manifestations. These included thrombotic thrombocytopenic purpura (TTP), right leg deep vein thrombosis (DVT), and eventually constitutional... | Recovered | ReactionOutcome | CC BY | 33488735 | 20,220,475 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Agitation'. | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | INFLIXIMAB, MESALAMINE, PROBIOTICS NOS | DrugsGivenReaction | CC BY | 33489084 | 18,863,547 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bone marrow failure'. | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | INFLIXIMAB, MESALAMINE, PROBIOTICS NOS | DrugsGivenReaction | CC BY | 33489084 | 18,863,547 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disseminated tuberculosis'. | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | INFLIXIMAB, MESALAMINE, PROBIOTICS NOS | DrugsGivenReaction | CC BY | 33489084 | 18,863,547 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Meningitis tuberculous'. | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | HYDROCORTISONE, MESALAMINE, VEDOLIZUMAB | DrugsGivenReaction | CC BY | 33489084 | 19,002,770 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Psychotic symptom'. | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | INFLIXIMAB, MESALAMINE, PROBIOTICS NOS | DrugsGivenReaction | CC BY | 33489084 | 18,863,547 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tuberculoma of central nervous system'. | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | HYDROCORTISONE, MESALAMINE, VEDOLIZUMAB | DrugsGivenReaction | CC BY | 33489084 | 19,002,770 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tuberculous pleurisy'. | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | HYDROCORTISONE, MESALAMINE, VEDOLIZUMAB | DrugsGivenReaction | CC BY | 33489084 | 19,002,770 | 2021 |
What was the administration route of drug 'INFLIXIMAB'? | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33489084 | 18,863,547 | 2021 |
What was the dosage of drug 'INFLIXIMAB'? | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | UNKNOWN | DrugDosageText | CC BY | 33489084 | 18,863,547 | 2021 |
What was the dosage of drug 'MESALAMINE'? | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | UNKNOWN | DrugDosageText | CC BY | 33489084 | 18,863,547 | 2021 |
What was the dosage of drug 'PROBIOTICS NOS'? | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | UNKNOWN | DrugDosageText | CC BY | 33489084 | 18,863,547 | 2021 |
What was the outcome of reaction 'Disseminated tuberculosis'? | Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn's disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be... | Recovering | ReactionOutcome | CC BY | 33489084 | 18,863,547 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.
Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for po... | FLUOROURACIL, LEUCOVORIN, METHOTREXATE, NIVOLUMAB, OXALIPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 33489132 | 18,997,192 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.
Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for po... | FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 33489132 | 18,967,261 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic function abnormal'. | Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.
Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for po... | FLUOROURACIL, LEUCOVORIN, METHOTREXATE, NIVOLUMAB, OXALIPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY | 33489132 | 18,997,192 | 2021-01 |
What was the administration route of drug 'LEUCOVORIN CALCIUM'? | Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.
Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for po... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33489132 | 18,967,261 | 2021-01 |
What was the administration route of drug 'LEUCOVORIN'? | Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.
Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for po... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33489132 | 18,997,192 | 2021-01 |
What was the administration route of drug 'NIVOLUMAB'? | Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.
Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for po... | Oral | DrugAdministrationRoute | CC BY | 33489132 | 18,997,192 | 2021-01 |
What was the administration route of drug 'OXALIPLATIN'? | Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.
Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for po... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33489132 | 18,997,192 | 2021-01 |
What was the dosage of drug 'LEUCOVORIN CALCIUM'? | Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.
Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for po... | 200 MILLIGRAM/SQ. METER, 1DOSE/2 WEEKS | DrugDosageText | CC BY | 33489132 | 18,967,261 | 2021-01 |
What was the dosage of drug 'NIVOLUMAB'? | Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.
Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for po... | 240MG/BODY (MONOTHERAPY) | DrugDosageText | CC BY | 33489132 | 18,997,192 | 2021-01 |
What was the dosage of drug 'OXALIPLATIN'? | Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.
Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for po... | 85 MILLIGRAM/SQ. METER, 1DOSE/2 WEEKS | DrugDosageText | CC BY | 33489132 | 18,967,261 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intentional product use issue'. | New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonec... | COBIMETINIB, IPILIMUMAB, VEMURAFENIB | DrugsGivenReaction | CC BY | 33489133 | 18,663,339 | 2021-01 |
What was the administration route of drug 'AMOXICILLIN\CLAVULANIC ACID'? | New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonec... | Oral | DrugAdministrationRoute | CC BY | 33489133 | 18,705,738 | 2021-01 |
What was the administration route of drug 'COBIMETINIB'? | New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonec... | Oral | DrugAdministrationRoute | CC BY | 33489133 | 18,705,738 | 2021-01 |
What was the administration route of drug 'DABRAFENIB'? | New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonec... | Oral | DrugAdministrationRoute | CC BY | 33489133 | 18,705,738 | 2021-01 |
What was the administration route of drug 'IPILIMUMAB'? | New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonec... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33489133 | 18,705,738 | 2021-01 |
What was the administration route of drug 'TRAMETINIB'? | New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonec... | Oral | DrugAdministrationRoute | CC BY | 33489133 | 18,705,738 | 2021-01 |
What was the administration route of drug 'VEMURAFENIB'? | New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonec... | Oral | DrugAdministrationRoute | CC BY | 33489133 | 18,705,738 | 2021-01 |
What was the dosage of drug 'AMOXICILLIN\CLAVULANIC ACID'? | New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonec... | 2.25 + 0.75 G/D | DrugDosageText | CC BY | 33489133 | 18,705,738 | 2021-01 |
What was the outcome of reaction 'Osteonecrosis of jaw'? | New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonec... | Recovered | ReactionOutcome | CC BY | 33489133 | 18,705,738 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Coronary artery occlusion'. | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | ASPIRIN, ENOXAPARIN, HEPARIN SODIUM, TICAGRELOR | DrugsGivenReaction | CC BY-NC-ND | 33489138 | 18,635,933 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemodynamic instability'. | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | ASPIRIN, ENOXAPARIN, HEPARIN SODIUM, TICAGRELOR | DrugsGivenReaction | CC BY-NC-ND | 33489138 | 18,635,933 | 2021-01 |
What was the administration route of drug 'ASPIRIN'? | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33489138 | 18,639,018 | 2021-01 |
What was the administration route of drug 'HEPARIN SODIUM'? | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33489138 | 18,639,018 | 2021-01 |
What was the administration route of drug 'TICAGRELOR'? | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33489138 | 18,639,018 | 2021-01 |
What was the dosage of drug 'ASPIRIN'? | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | 300 MG | DrugDosageText | CC BY-NC-ND | 33489138 | 18,635,933 | 2021-01 |
What was the dosage of drug 'ENOXAPARIN'? | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | 300 MG | DrugDosageText | CC BY-NC-ND | 33489138 | 18,635,933 | 2021-01 |
What was the dosage of drug 'HEPARIN SODIUM'? | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | 7500 IU | DrugDosageText | CC BY-NC-ND | 33489138 | 18,635,933 | 2021-01 |
What was the dosage of drug 'TICAGRELOR'? | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | 180 MG | DrugDosageText | CC BY-NC-ND | 33489138 | 18,635,933 | 2021-01 |
What was the outcome of reaction 'Coronary artery occlusion'? | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | Fatal | ReactionOutcome | CC BY-NC-ND | 33489138 | 18,635,933 | 2021-01 |
What was the outcome of reaction 'Coronary artery thrombosis'? | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | Fatal | ReactionOutcome | CC BY-NC-ND | 33489138 | 18,639,018 | 2021-01 |
What was the outcome of reaction 'Haemodynamic instability'? | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | Fatal | ReactionOutcome | CC BY-NC-ND | 33489138 | 18,635,933 | 2021-01 |
What was the outcome of reaction 'Heparin-induced thrombocytopenia'? | Coronary thrombosis due to heparin-induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent.
In case of unexplained post-PCI coronary thrombosis, a HIT should be always considered. A pragmatic approach with bivalirudin may be reasonable, even in absence of confirmed laboratory ... | Fatal | ReactionOutcome | CC BY-NC-ND | 33489138 | 18,639,018 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Torsade de pointes'. | Torsades de pointes after prolonged intravenous amiodarone therapy for atrial fibrillation.
Amiodarone can induce TdP; therefore, it should be avoided as a first choice for therapy in patients without heart disease. Careful QT interval monitoring, especially during intravenous use, can prevent development of this life-... | AMIODARONE HYDROCHLORIDE, BISOPROLOL, METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33489188 | 18,642,824 | 2021-01 |
What was the dosage of drug 'BISOPROLOL'? | Torsades de pointes after prolonged intravenous amiodarone therapy for atrial fibrillation.
Amiodarone can induce TdP; therefore, it should be avoided as a first choice for therapy in patients without heart disease. Careful QT interval monitoring, especially during intravenous use, can prevent development of this life-... | 2.5 mg (milligrams). | DrugDosage | CC BY-NC-ND | 33489188 | 18,642,824 | 2021-01 |
What was the outcome of reaction 'Torsade de pointes'? | Torsades de pointes after prolonged intravenous amiodarone therapy for atrial fibrillation.
Amiodarone can induce TdP; therefore, it should be avoided as a first choice for therapy in patients without heart disease. Careful QT interval monitoring, especially during intravenous use, can prevent development of this life-... | Recovered | ReactionOutcome | CC BY-NC-ND | 33489188 | 18,642,824 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sarcoidosis'. | Diffuse lesions secondary to sarcoidosis mimicking widespread metastatic breast cancer: A case report.
This case of sarcoidosis mimicking metastatic breast cancer serves as a reminder of the need to consider differential diagnoses even when the clinical scenario and imaging findings are highly suggestive of metastases.... | ANASTROZOLE, TRASTUZUMAB | DrugsGivenReaction | CC BY | 33489200 | 20,577,721 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neoplasm progression'. | Secondary brain metastases of Ewing's sarcoma presenting with collapse after 6 years of complete remission.
Routine brain imaging with MRI and long-term follow-up of Ewing's sarcoma could be the way to move forward by increasing our understanding in this area, as well as improving treatment and long-term outcome for pa... | DOXORUBICIN, ETOPOSIDE, IFOSFAMIDE, VINCRISTINE | DrugsGivenReaction | CC BY | 33489215 | 18,907,873 | 2021-01 |
What was the dosage of drug 'DOXORUBICIN'? | Secondary brain metastases of Ewing's sarcoma presenting with collapse after 6 years of complete remission.
Routine brain imaging with MRI and long-term follow-up of Ewing's sarcoma could be the way to move forward by increasing our understanding in this area, as well as improving treatment and long-term outcome for pa... | RECEIVED 8 CYCLES | DrugDosageText | CC BY | 33489215 | 18,933,287 | 2021-01 |
What was the dosage of drug 'VINCRISTINE SULFATE'? | Secondary brain metastases of Ewing's sarcoma presenting with collapse after 6 years of complete remission.
Routine brain imaging with MRI and long-term follow-up of Ewing's sarcoma could be the way to move forward by increasing our understanding in this area, as well as improving treatment and long-term outcome for pa... | UNK, CYCLIC (8 COURSES OF VIDE) | DrugDosageText | CC BY | 33489215 | 18,898,550 | 2021-01 |
What was the outcome of reaction 'Neoplasm progression'? | Secondary brain metastases of Ewing's sarcoma presenting with collapse after 6 years of complete remission.
Routine brain imaging with MRI and long-term follow-up of Ewing's sarcoma could be the way to move forward by increasing our understanding in this area, as well as improving treatment and long-term outcome for pa... | Recovering | ReactionOutcome | CC BY | 33489215 | 18,907,873 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Alopecia'. | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | LETROZOLE, PACLITAXEL | DrugsGivenReaction | CC BY | 33489227 | 18,618,573 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Epidermal necrosis'. | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | LETROZOLE, PACLITAXEL | DrugsGivenReaction | CC BY | 33489227 | 18,618,573 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nail toxicity'. | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | LETROZOLE, PACLITAXEL | DrugsGivenReaction | CC BY | 33489227 | 18,618,573 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Onycholysis'. | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | LETROZOLE, PACLITAXEL | DrugsGivenReaction | CC BY | 33489227 | 18,618,573 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Palmar-plantar erythrodysaesthesia syndrome'. | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | LETROZOLE, PACLITAXEL | DrugsGivenReaction | CC BY | 33489227 | 18,618,573 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin exfoliation'. | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | LETROZOLE, PACLITAXEL | DrugsGivenReaction | CC BY | 33489227 | 18,618,573 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin haemorrhage'. | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | LETROZOLE, PACLITAXEL | DrugsGivenReaction | CC BY | 33489227 | 18,618,573 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin lesion'. | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | LETROZOLE, PACLITAXEL | DrugsGivenReaction | CC BY | 33489227 | 18,618,573 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin ulcer'. | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | LETROZOLE, PACLITAXEL | DrugsGivenReaction | CC BY | 33489227 | 18,618,573 | 2021-01 |
What is the weight of the patient? | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | 70 kg. | Weight | CC BY | 33489227 | 18,618,573 | 2021-01 |
What was the administration route of drug 'PACLITAXEL'? | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33489227 | 18,618,573 | 2021-01 |
What was the outcome of reaction 'Alopecia'? | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | Recovered | ReactionOutcome | CC BY | 33489227 | 18,618,573 | 2021-01 |
What was the outcome of reaction 'Nail toxicity'? | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | Recovered | ReactionOutcome | CC BY | 33489227 | 18,618,573 | 2021-01 |
What was the outcome of reaction 'Palmar-plantar erythrodysaesthesia syndrome'? | An unusual and severe case of paclitaxel-induced hand-foot syndrome.
Although paclitaxel is known to cause mild skin toxicity, it may induce severe HFS requiring drug withdrawal. Patients with high disease burden might receive prolonged paclitaxel chemotherapy. Hence, a grade 2 toxicity would better indicate withdrawal... | Recovered | ReactionOutcome | CC BY | 33489227 | 18,618,573 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infusion related reaction'. | Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.
Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodie... | CETUXIMAB, CHLORPHENIRAMINE MALEATE, DEXAMETHASONE SODIUM PHOSPHATE, FAMOTIDINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN, PANITUMUMAB | DrugsGivenReaction | CC BY | 33489709 | 19,306,605 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Toxicity to various agents'. | Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.
Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodie... | CETUXIMAB, DEXAMETHASONE SODIUM PHOSPHATE, FAMOTIDINE, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY | 33489709 | 19,230,934 | 2021-01 |
What was the administration route of drug 'CETUXIMAB'? | Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.
Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodie... | Other | DrugAdministrationRoute | CC BY | 33489709 | 19,306,605 | 2021-01 |
What was the administration route of drug 'PANITUMUMAB'? | Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.
Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodie... | Intravenous drip | DrugAdministrationRoute | CC BY | 33489709 | 19,306,605 | 2021-01 |
What was the dosage of drug 'CHLORPHENIRAMINE MALEATE'? | Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.
Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodie... | 5 mg (milligrams). | DrugDosage | CC BY | 33489709 | 19,306,605 | 2021-01 |
What was the dosage of drug 'DEXAMETHASONE'? | Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.
Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodie... | 1.65 mg (milligrams). | DrugDosage | CC BY | 33489709 | 19,247,283 | 2021-01 |
What was the dosage of drug 'LEUCOVORIN CALCIUM'? | Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.
Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodie... | 7 CYCLIC | DrugDosageText | CC BY | 33489709 | 19,230,934 | 2021-01 |
What was the dosage of drug 'LEUCOVORIN'? | Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.
Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodie... | MFOLFOX6 REGIMEN | DrugDosageText | CC BY | 33489709 | 19,306,605 | 2021-01 |
What was the dosage of drug 'LORATADINE'? | Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.
Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodie... | 50 mg (milligrams). | DrugDosage | CC BY | 33489709 | 19,247,283 | 2021-01 |
What was the outcome of reaction 'Infusion related reaction'? | Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer.
Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodie... | Recovered | ReactionOutcome | CC BY | 33489709 | 19,306,605 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute respiratory failure'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bone marrow failure'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Brain herniation'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'C-reactive protein increased'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac failure'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac ventricular thrombosis'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cerebral haemorrhage'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cerebrovascular disorder'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Embolism'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Endocarditis'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Full blood count decreased'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal injury'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Heart injury'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intracranial pressure increased'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Liver injury'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Muscle injury'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Overdose'. | Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: A case report and review of the literature.
This is the first published case report of a child with acute lymphatic leukemia developing a fatal mucormycosis during blinatumomab treatment. The patient showed multiple,... | ACYCLOVIR, BLINATUMOMAB, CASPOFUNGIN, CEFTRIAXONE, GENTAMICIN, MEROPENEM, MORPHINE SULFATE, TEICOPLANIN | DrugsGivenReaction | CC BY-NC-ND | 33489743 | 19,721,335 | 2021-06 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.